Brief: Argenx Shares Data From Phase 3 Trial For Vyvgart And Vyvgart Hytrulo

argenx SE

16/04/2024 06:08

April 16 (Reuters) - argenx SE  ARGX.BR :
    * ARGENX DATA HIGHLIGHT EVIDENCE THAT VYVGART AND VYVGART
HYTRULO
DRIVE TRANSFORMATIVE OUTCOMES FOR PATIENTS WITH DEBILITATING
AUTOIMMUNE DISEASE
    * DATA FROM ITS PHASE 3 ADHERE TRIAL EVALUATING VYVGART
HYTRULO
(EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) IN PATIENTS WITH
CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) WERE
PRESENTED FOR THE FIRST TIME TO THE MEDICAL COMMUNITY DURING THE
CLINICAL TRIALS PLENARY SESSION AT THE AMERICAN ACADEMY OF
NEUROLOGY
    * CLINICAL TRIAL AND REAL-WORLD DATA ACROSS SEVEN POSTERS
AND
PRESENTATIONS THAT CONTINUE TO REINFORCE VYVGART AND VYVGART
HYTRULO AS A TRANSFORMATIVE TREATMENT OPTION

Source text for Eikon:  urn:newsml:reuters.com:*:nGNE3GrQqj
Further company coverage:  ARGX.BR 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))